XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology

Basit Öğe Kaydı
dc.authoridbayoglu, ibrahim vedat/0000-0002-0481-1084
dc.authoridduran, Ayse Ocak/0000-0002-1703-726X
dc.authoridBeşiroğlu, Mehmet/0000-0002-1171-8320
dc.authoridHacıbekiroğlu, İlhan/0000-0002-0333-7405
dc.authoridSevinç, Alper/0000-0002-0499-8918
dc.authoridTanriverdi, Ozgur/0000-0002-0598-7284
dc.authoridaksoy, asude/0000-0002-5609-9658
dc.authorwosidSevinc, Alper/KFQ-6440-2024
dc.authorwosidbayoglu, ibrahim vedat/HKN-8074-2023
dc.authorwosidduran, Ayse Ocak/ABA-7090-2021
dc.authorwosidBeşiroğlu, Mehmet/AEQ-3080-2022
dc.authorwosidBahçeci, Aykut/Z-3961-2019
dc.authorwosidHacıbekiroğlu, İlhan/JCN-7264-2023
dc.authorwosidSevinç, Alper/KPA-4519-2024
dc.contributor.authorDuran, Ayse Ocak
dc.contributor.authorKaraca, Halit
dc.contributor.authorBesiroglu, Mehmet
dc.contributor.authorBayoglu, Ibrahim Vedat
dc.contributor.authorMenekse, Serkan
dc.contributor.authorYapici, Heves Surmeli
dc.contributor.authorYazilitas, Dogan
dc.date.accessioned2024-06-12T11:08:25Z
dc.date.available2024-06-12T11:08:25Z
dc.date.issued2014
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: XELOX plus bevacizumab (XELOX-Bev) and FOLFIRI plus Bevacizumab (FOLFIRI - Bev) treatments are an effective strategies patients with metastatic colorectal cancer (mCRC). The aim of this study was to compare efficacy of first-line XELOX-Bev treatment vs FOLFIRI-Bev treatment for mCRC. Materials and Methods: A total of 409 patients with mCRC who received chemotherapy were included and divided into 2 groups. Group 1 (n=298) received XELOX-Bev and Group 2 (n=111) FOLFIRI-Bev. Comparisons were made in terms of overall (OS) and progression-free (PFS) survival, response rate (RR), and grade 3-4 toxicity. Results: Median follow-up was 11 months in Group 1 and 15 months for Group 2. Complete remission was observed in 29 (9.7%) and 2 (1.8%) patients, partial remission in 139 (46.6%) and 27 (24.5%), stable disease in 88 (29.5%) and 49 (44.1%) and progressive disease in 42 (14.1%) and 33 (30.0%) patients in Group 1 and 2, respectively. Median OS was 25 months (range 2-57 months, 95% CI; 22.2-27.7) for Group 1 and 20 months (range 1-67 months, 95% CI; 16.8-23.1) for Group 2 (p=0.036). Median PFS was 9.6 months (range 2-36 months, 95% CI; 8.8-10.4) for Group 1 and 9 months (range 1-44 months, 95% CI; 7.4-10.5) for Group 2 (p=0.019). Objective RR was 56.4% in Group 1 and 26.1% in Group 2 (p<0.001). Conclusions: First-line XELOX-Bev is more effective with a better response rate, prolongation of median PFS/OS, and a superior safety profile compared with FOLFIRI-Bev.en_US
dc.identifier.doi10.7314/APJCP.2014.15.23.10375
dc.identifier.endpage10379en_US
dc.identifier.issn1513-7368
dc.identifier.issue23en_US
dc.identifier.pmid25556478en_US
dc.identifier.scopus2-s2.0-84921759507en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage10375en_US
dc.identifier.urihttps://doi.org/10.7314/APJCP.2014.15.23.10375
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22425
dc.identifier.volume15en_US
dc.identifier.wosWOS:000351058400056en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAsian Pacific Organization Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal Of Cancer Preventionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMetastatic Colorectal Canceren_US
dc.subjectXELOX Plus Bevacizumaben_US
dc.subjectFOLFIRI Plus Bevacizumaben_US
dc.subjectComparisonen_US
dc.subjectAdvanced Colorectal-Canceren_US
dc.subjectSingle-Agent Bevacizumaben_US
dc.subjectCell Lung-Canceren_US
dc.subjectPhase-Iiien_US
dc.subjectMaintenance Therapyen_US
dc.subjectElderly-Patientsen_US
dc.subjectChinese Patientsen_US
dc.subjectEfficacyen_US
dc.subjectSafetyen_US
dc.subjectCapecitabineen_US
dc.titleXELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncologyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu